We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Women in Serbia as late presenters-an issue of concern.
- Authors
Dragovic, G; Ranin, J; Salemovic, D; Kusic, J; Jevtovic, D
- Abstract
Most of the clinical trials looking at the efficacy and side effects of highly active antiretroviral therapy (HAART) have been conducted primarily on HIV-infected males. So, we conducted a study to determine the factors influencing prognosis of HIV/AIDS and outcome in HIV/AIDS women on HAART, in a resource-limited settings. A cross-sectional study was performed on women, with HIV infection, who initiated HAART between 1st January 1998 and 31st December 2010, at the HIV/AIDS Center of the University Hospital for Infectious and Tropical Diseases in Belgrade, Serbia, with regular clinical and laboratory check-ups. SPSS-version-11.0 software, Univariate and stepwise Multivariate logistic regression analysis together, with the Kaplan-Meier analysis, were used to estimate risk factors influencing prognosis and outcome in HIV/AIDS women. Written consent was obtained. A total of 230 women were followed for 8.2±3.4 years (range 1-12). Durring the follow-up, 26 patients died. The mean age of the patients at HAART initiation was 37±9.7 years. Clinical AIDS at presentation was observed in 43.9% of the patients, while 80% of them had CD4 cell counts below 200 cell/mm3. Univariate and stepwise multivariate analysis have shown that the progression to death was associated with basal CD4 counts below 100 cells/µL (OR 3.0 95% CI 1.7-8.4, P=0.02) and HCV co-infection (OR 2.6 95% CI 1.0-6.6, P=0.03). However the NNRTI based regimens and good adherence to HAART (OR 0.2, 95% CI 0.09-0.6, P=0.005 and OR 0.3, 95% CI 0.1-0.66, P=0.03, respectively), all prevented death. Although in patients with sustained viral suppression the CD4 counts varied significantly, these did not affect overall survival (p=0.21, log rank) If HIV infected women with advanced HIV-related immunodeficiency reach and maintain optimal viral suppression during HAART, regardless of the level of immune recovery, and if they continue to maintain this achievement up to a mean 8 years of treatment, their prognosis may be fairly good even in a resource limited settings.
- Subjects
THERAPEUTICS; HIV infections; HIV-positive women; HIV-positive persons; HIGHLY active antiretroviral therapy; HIV
- Publication
Journal of the International AIDS Society, 2012, Vol 15, p1
- ISSN
1758-2652
- Publication type
Article
- DOI
10.7448/IAS.15.6.18300